Skip to main content
All lobbying filings

ARENTFOX SCHIFF LLP

ARENTFOX SCHIFF LLP filed a Q1 report for ORGANOGENESIS INC. on April 16, 2026, reporting $20,000 in lobbying income.

Lobbying for ORGANOGENESIS INC. · Biotech company

All filings by ARENTFOX SCHIFF LLP · Everything ORGANOGENESIS INC. has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 16, 2026
Income
$20,000
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2

Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products (CY2026) Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing products (CY2026) H.R. 5768 and S. 2561 (Skin Substitute Access and Payment Reform Act of 2025), entire bill H.R.6852 (Advanced Wound Care and Regenerative Medicine Access and Reform Act), entire bill

Food and Drug Administration policy on chronic wound healing products

 Bills named in this filing 3
  • H.R. 5768
    Skin Substitute Access and Payment Reform Act
  • S. 2561
    Skin Substitute Access and Payment Reform Act of 2025
  • H.R. 6852
    Advanced Wound Care and Regenerative Medicine Access and Reform Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem